Software results from two-year collaboration between CPI, Intellegens, and industry partners
Cambridge, UK – 2 September, 2025 – Intellegens today announced the availability of a new software solution designed to accelerate and streamline process development for oligonucleotide therapies through advanced data integration and machine learning. Alchemite™ for Oligonucleotide Manufacturing is the outcome of a two-year collaborative project led by Intellegens and CPI to develop and validate digital tools that apply machine learning (ML) to oligonucleotide manufacturing. As previously announced, the project was supported by the Innovate UK ‘Transforming Medicine Manufacturing’ programme and had direct input from six leading research partners, including top ten pharma companies such as Novartis and specialist biotech companies such as Silence Therapeutics.
Upcoming webinar
How machine learning can accelerate oligonucleotide process development
Date: Tuesday, 23 Sept, 2025
Time: 16:00 UK time // 11:00 US Eastern
Guest speaker from CPI.
Supporting images
Click on the image to download a JPEG.
